Investors send the RNAi company’s stock down on news of follow-on offering.
|
Combo drugs work for heart disease; the Medicis-Inamed deal is delayed; more questions about Vioxx marketing; Dharmacon to supply siRNA library.
|
AMO snaps up Quest; Sirna takes RNAi through Phase I; Bayhill raises $35.4 million; Glaxo’s vaccine approved.
|
After the hype, and then the lull, biotechs are making progress in pushing RNAi therapies into real-world treatments and real-deal revenues.
|